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 Tracheobronchial malacia is a commonly under-diagnosed condition that results 
in difficulty breathing. The use of a tracheobronchial stent is the best course of treatment 
for patients whose quality of life has deteriorated due to malacia; unfortunately stents 
need replacing after issues with inflammation, migration, or eventual stent-breakdown 
resulting in fistula formation.  
The purpose of this thesis is to use three-dimensional (3D) printing technology to 
improve on existing stents through designing and printing a bioresorbable/biodegradable 
tracheobronchial stent that can treat tracheobronchial malacia. This was undertaken by 
testing three biologically favorable materials, type I collagen, polycaprolactone (PCL), 
and thermoplastic polyurethane (TPU), with desirable qualities that may result in 
producing stents with idealized properties. These materials underwent print-compatibility 
testing to determine whether, following a simple tubular stent geometry similar to the 
Dumon silicone stent, these materials can be manufactured into a prototype stent via 
innovative 3D printing methods. The resulting stents were mechanically tested and 
compared to the industry standard Dumon silicone stent. 
We demonstrated that PCL is fused deposition modeling (FDM) printing-
compatible, that TPU is potentially viable as a silicone alternative that is biologically 
degradable, and that type I collagen can potentially be cured, using injection molding 
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CHAPTER 1. UNDERSTANDING THE PROBLEM MEDICALLY 
 
 
1.1 History of Stents 
 
 This research proposes the use of three-dimensional printing technology to create 
implantable tracheobronchial stents. To examine this, a detailed overview of stent 
technology over the course of history, as well as modern technology employed today, 
will be presented.  
Tracheobronchial malacia is a commonly under-diagnosed acquired condition in 
adults, occurring within an estimated 10% of the population [1]. This condition is 
characterized by tracheal cartilage flaccidity, a reduced anterior-posterior airway caliber, 
and a widened posterior membranous tracheal wall; all of which result in a temporary 
collapse of up to 50% or more of the trachea during eating, coughing, crying, and in 
extreme cases, exhaling [2, 3, 4]. Type I and Type III tracheobronchial malacia are our 
targets. Type I is congenital (birth defect) associated with esophageal atresia, or 
trachoesophageal fistula formation. Type III is acquired through inflammatory conditions 
like relapsing polychondritis (constant inflammation of cartilaginous structures of the 
nose, ears, and laryngotracheobronchial tree in particular) or chronic tracheal infections, 
as well as from prolonged intubation for medical reasons. Long-term treatment for this 
condition involves the use of stents to improve the peripheral airway clearance and 
improve quality of breathing. 
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Airway stents have been around and in use for close to 100 years. The earliest 
among them appearing in 1915 through the work of Gustav Killian, known as the ‘Father 
of Bronchoscopy’, and his students Brünings and Albrecht [5]. Many of the modern 
airway stents began as endoprosthesis developed for implantation into the vascular 
system. These implants were then adapted through minor modifications for central airway 
usage. While in the early 1900s, the first airway stents were rubber, 1933 marked the use 
of the first metal-based stent to treat laryngeal bony stenosis of a 2-year-old boy, by 
Canfield and Norton [6]. Montgomery (Fig. 1.1) closely followed this in 1965 via the 
creation of a silicone-rubber, T-shaped tube stent [7]. The year 1990 saw stent placement 
officially become an acknowledged clinical, endoscopic treatment when Dumon 
introduced a stent made of silicone, specialized for the trachea and bronchi [8]. Since 
then, Dumon silicone stents are the most commonly implanted stent types in 
tracheobronchial surgeries globally.  
 
 




 1.2 Stents Today 
 Today stents like the Dumon (Fig. 1.2) are employed for three major reasons: 
primarily to reestablish airway patency, to provide support to weakened cartilage rings 
when malacia occurs, or for providing a sealant when dealing with dehiscences and 
fistulas in the esophagus [9]. Though not all prototypes were able to withstand the 
passage of time, many types of stents still exist, and can be labeled as one of four chief 
categories: metallic stents, covered metallic stents, polymer stents (like the Dumon), or 
hybrids of metal combined with polymers such as silicone (like the Dynamic stent) [9]. 
Metal stents tend to be made of either stainless steel or Nitinol, a nickel and titanium 
alloy, while polymer stents are almost primarily silicone [10]. Tissue response to a stent, 
and the overall outcome of an endoscopic procedure, relies heavily on the material 
composition of a stent and its resulting biomechanical properties [9], justifying the 




Figure 1.2. Silicone studded Dumon stent. Original design, product of 
Kaptex Healthcare Ltd. 
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 Currently used stents are variable, depending on the nature of the particular 
disease intended to be treated. Each of these stents uses materials foreign to the body, 
although made biologically inert through modification. Much research of the following 
stent types and designs, principally those developed or studied by Lutz Freitag, will be a 
beneficial basis for future research at the University of South Carolina for a fresh, 
innovative range of stent materials. These are to be based instead on bioresorbable or 
biodegradable, polymeric materials better suited to integration and gradual breakdown in 
the body, bringing the idealized stent closer to reality. 
 
1.2.1 Polymer Stents 
 Among the stents of today, polymer stents like the aforementioned and popular 
Dumon stent are most frequently used, and have become the ‘de facto gold standard’ of 
the endoscopic world [8,11]. Composed of coated silicone, the shape resembles a hollow 
tube with small rounded studs along the outside, while the interior surface is extremely 
smooth. Partly due to their simplicity, Dumon stents are extremely versatile and come in 
a range of sizes to allow for treatment of tracheal and bronchial stenosis from children 
through adults. The stent can be repositioned and replaced with ease. These stents are 
also prone to migration occasionally. 
 





 A polyester-mesh stent, very similar in design to the Dumon, is known as the 
Polyflex stent (Fig. 1.3), and is even more adaptable than tube-shaped stents. This 
flexibility is due to its circumferential length change when local compression is applied. 
The addition of ‘tungsten spots’ at particular points in the mesh allow for visibility of the 
stent in chest X-rays. The smoothness of the surface of the Polyflex stent makes it much 
more prone to migration compared to other solid body tube stents. Correction of the 
migration risk was attempted by the addition of spike-shaped silicone structures to the 
exterior of the Polyflex and tested in animal models. This, however, was found to cause 
severe granulation of local tissue [12]. 
 The Montgomery stents have been modified slightly from the original 1965 
design, having changed the composite material and the diameters of the T-tube; they are 
primarily employed to treat tracheal stenosis starting from the vocal cords to further into 
the trachea and bronchi. Stent migration is not possible with the Montgomery, as the use 
of this stent necessitates a surgical tracheostomy in addition to the procedure. However, 
this affects patient speech capability. Lymphatic flow and blood flow are not impaired in 
any way, making this stent safest to employ for tracheal stenosis in this anatomical region. 
 
1.2.2 Metal Stents 
 Metal stents like the Palmaz steel stent (Fig. 1.4) are mesh stents requiring 
balloon expansion during deployment into the tracheobronchial region; these were 
originally developed for use in the biliary duct and blood vessels [13], and have been 
successfully used in airways due to the ability to ‘mold’ the stent by the endoscopist, in 
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vivo, via manipulation with dilatation forceps or an angioplasty balloon. Epithelialization 
(the migration of living cells into the implant to integrate the implant into the surrounding 
tissue) occurs within weeks of implantation, but the stent is plastically inflexible as far as 
the mechanical properties are considered. Although granulation formation is far less than 
other metal stents, fluctuating pressure from coughing could permanently deform the 
stent, requiring that serious caution be exercised when choosing this treatment route. 





Figure 1.4. Metal stents used today. Products of Boston Scientific. The Palmaz stent (4a), 
Wallstent (4b), and Ultraflex Strecker covered stent (4c), are all flexible mesh stents. 
 
 
 The Wallstent (Fig. 1.4) is also a woven metallic mesh, but is coated with a 
polyurethane layer [14]. This design will not collapse when bent or compressed, making 
it unique among metallic stents. Resistance to collapse allows for the stent to be used 
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throughout the trachea and less-uniform regions of the bronchial tree. Like many metallic 
stents, the Wallstent shares a similar problem of causing granulation tissue formation.  
As the Wallstent is completely compressed, lengthening occurs, while when partially 
compressed the stent will shorten. The uncovered edges are slightly pointed, thus any 
movement against the local mucosa will cause a tissue granulation response. 
 Another metal stent, the Ultraflex Strecker Stent (Fig 1.4), is better adapted to 
kinked, irregularly shaped, or particularly smooth airways [9]. The wire filaments, which 
are knitted to form this stent, are made of Nitinol and allow for epithelialization of the 
stent such that functioning cilia can exist within the stent. The Ultraflex can be used to 
treat a broad range of tracheobronchial stenosis, including those caused by tumors, and 
can be used to seal airway fistulas to the pleural cavity, or to the esophagus. Although the 
mesh allows for function of the mucociliary escalator within the airway, once again 
granulation tissue formation is a problem to be considered with this stent, along with 
tissue growth between the mesh.  
 A summary of each of these stent types, their material composition and subtypes 
included, are found in Table 1.1. Additionally, benefits and shortcomings of each stent 






















1.2.3 Idealized Stent 
 As mentioned throughout, these existing materials do not satisfy all requirements 
for an ideal stent, though many are functional and useful tools. Nearly all have reported 
some form of complications, usually formation of tissue granulation (mainly in metal 
stents), mucostatis due to necrosis or occlusion of the ciliary system within the airways, 
and stent migration (particularly in Dumon, Noppen, and Polyflex polymer stents) 
[9,15,16]. Ideal stent properties have been outlined after multiple experiments by various 
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authors. These much desired and superlative properties require that stents are limited in 
the amount of migration, tissue morbidity and mortality, additionally are easily removed 
and placed, result in minimum granulation tissue formation, and maintain the potency of 
the laminal tissue which the stents are placed in contact with [10,15] such that the natural 
mucociliary escalator system in the airways is undamaged. In addition, an economical or 
cost effective product would also be more hospital, and patient-friendly. 
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Figure 2.1. A sample of the different types of 3D printing and 3D manufacturing available today. While 
the fasted growing of the categories is AM, and of that, FDM and Bio-printing, the ‘bio-printing’ process is 
still experimental and under development. 
 
 In this research, FDM (Fig. 2.1) printing is the primary method employed for 
biodegradable/biocompatible stent design. Among its many benefits is the advantageous 
feature of obtaining a device directly from the input 3D design within a matter of hours, 
which makes it the most established and practical additive manufacturing (AM) method 
in the medical field today [17, 18]. 
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 Creation of a three-dimensional stent requires specialized equipment. While an 
idealized stent needs to fit certain biological parameters and a set of engineering 
parameters to make such a stent possible, economical parameters such as cost-
effectiveness are equally crucial. Depending on the material state, the stent is three-
dimensionally manufactured using a particular specialized process. For liquid-state 
materials, such as liquefied metal alloys, stereolithography (SLA) is employed. For solid 
materials in filament form, fused deposition modeling (FDM) is used. In this research we 
focused on fused deposition modeling printing. Among its many benefits, FDM printing 
allows manufacturing of stents that are customizable for individual patients; a design 
aspect in much demand in the medical sector. With rapid advancements in this 3D 
printing field married to medicine, pioneering the creation of the ideal stent can be that 
much closer at hand.  
 
2.1.1 Techniques of 3D Printing  
 Various methods of manufacturing stents are used today (Fig. 2.1), and all of 
these methods are regarded as “three-dimensional” (3D) printing. However each method 
has advantages and disadvantages. In this section, we describe the various 3D printing 
methods. For tracheobronchial stents, the method of manufacture depends heavily on the 
material. 
 Metallic stents are traditionally manufactured with subtractive manufacturing, in 
which a laser cuts a piece of metal according to input parameters from a computer aided 
design (CAD) type software to create a special netted wire mesh; 3D printing methods for 
metal stent manufacturing involve selective laser sintering (SLS), in which metal or metal 
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alloy powders are partially melted locally in order to conglomerate and form a solid 
netted stent layer by layer [19-22]. Once cut, the stent is then prepared for coating using 
techniques like chemical finishing and laser deburring. The stent can then be coated via 
electroplating, or simply undergo electro-polishing. These processes are undertaken in 
order to improve biocompatibility or to bestow biologically inert characteristics to the 
stent [19, 20].  
 Metal injection molding is a method in which liquefied metal is forced through a 
mold to create the final product geometry [21]. Assembly of wire filaments is a method in 
which metal or metal alloys are made into filaments and assembled into a final mesh 
design. These are alternative methods that can be employed when manufacturing a metal 
stent, but depend on the metallic stent design in question [19]. 
  Injection molding methods are primarily used for silicone polymer stent 
manufacturing. Formation of the mold, however, must be completely personalized to the 
patient, leading to great expense and time-consumption to achieve the final cured 
geometry [23]. Because of this, many of the silicone stents available on the market today 
are simply tubular structures, similar to the ‘gold standard’ Dumon stent (Fig. 1.2). 
 While customization of a mold is time consuming from a manufacturing 
standpoint, customization of products is the ideal standard for reducing overall cost and 
care-time in the health sector, particularly from the standpoint of the patient and of 
healthcare companies. For this type of personalized manufacturing (that is, for stents 
made of metal and silicone), additive manufacturing (AM) is the de facto method [24-27]. 
AM is the fastest growing printing method, particularly in the medical sector [18]; this is 
due to AM’s capability to produce small-scale tools or products with a berth of detail. 
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AM can make use of three types of materials, using different specialized sub-techniques 
for building with each material. As aforementioned, SLS manufacturing, a type of AM, is 
used for solid materials, but specifically metal; for polymer resins in liquid form, 
stereolithography (SLA) is preferred, although metal powders can also be combined with 
liquid polymer to create a finished metal part [73]; both powders and pellets are made 
into filaments for which fused deposition modeling (FDM) is the method of choice, both 
of these also being AM subtypes. 
 
2.2 Materials for Printable Stents 
 
 
Figure 2.2. Examples of forms of additive manufacturing which are specialized for particular material 
types. Metals and metal-alloys are used in powder form and are processed using SLS printing; many 
polymers and ceramics come in powder form, although polymer resins are also available for SLA printing 
methods. Polymers are also found in filament form and available as spools. Biologicals involve 
introduction of live cells to print tissue, but this is done by first printing a scaffold and later introducing 
cells into the scaffold to create grafts, etc. As of yet there are no printers that can directly print living, 
wholly undamaged cells. 
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 All material considerations for stents in this research were required to be either 
bioresorbable, biodegradable, or biocompatible; therefore these key terms must be 
clarified for the reader. The generally accepted definitions are as follows.  
 Materials that are ‘bioresorbable’ are completely eliminated from the body via 
natural pathways like metabolizing or filtration of the byproducts, after bulk degradation 
of that material [28, 29].  
 ‘Biodegradable’ materials are defined as solid materials (including gels, grafts, 
and implants), often of polymeric nature, that undergo macromolecular degradation in 
vivo. This breakdown results in byproducts or fragments that do not necessarily exit the 
body, but are removed from the site of action [28, 29]. 
 While there is a broader definition for those materials termed ‘biocompatible’, the 
FDA and European Society for Biomaterials (ESB) accepted definition of a medical 
device that is biocompatible states the material should not elicit any undesirable systemic 
or local effects, (such as toxicity or carcinogenic effects) [30, 31]. It is further stated that 
the biocompatible material should elicit an ‘appropriate and beneficial’ cellular or tissue 
response for that given situation. 
 Existing stents tend not to be biocompatible, but rather are biologically inert at 
best, and employ a limited set of material types, namely silicone, metal-alloys such as 
Nitinol, other metals such as Teflon [32, 33] or stainless steel [34], or a combination of 
any of the aforementioned elements. In order to more closely achieve an idealized stent, 
other materials with better biocompatibility are a necessity. Material science has grown in 
leaps and bounds, producing many polymers with biomimicry capabilities, or substances 
that can harmlessly breakdown over a determined amount of time and are then flushed 
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from the body via the usual rheological route. Elements native to the body have also been 
aggressively studied and put to novel uses while maintaining the natural properties that 
they are biologically specialized for. 
In this research, we are focusing on FDM, which has certain material 
requirements. Three types of materials were investigated for this research—ranging from 
most natural and biodegradable, to least natural but biologically compatible. The first, 
collagen type I, is a native, biological material; the second, middle-spectrum material, 
polycaprolactone, is highly biocompatible and biodegradable but is also a synthetic/soft-
biopolymer; the third, thermoplastic polyurethane (TPU), is a promising biocompatible 
polymer. These materials have yet to be tested for stenting, or yet to be proven as 
manufacturable through the novel methods of FDM printing to create functional 
tracheobronchial stents.  
 Collagen is the most natural of the materials we investigated; it is also the most 
abundant in the mammalian body, making up 25-35% of the body’s total protein content 
[35, 36]. This material is type I “fibrillar protein” collagen. On the nano-scale with its 
highly organized alpha helices base, throughout till the micro-level with its intricately 
structured fiber bundles, the architecture of collagen type I boasts high tensile strength 
[37-40]. Viscoelastic properties of collagen, particularly as a hydrogel [41, 42], also favor 
the use of type I collagen as a biomaterial for stent making. Additionally, cells easily 
attach to and degrade collagen, allowing for reintegration of living tissue and production 
of new collagen intercellularly in areas surrounding the implanted biomaterial [36].  
 Collagen is optimized for laying the structural foundations for a variety of tissues 
in the body, making collagen type I conducive to rebuilding a tracheobronchial passage 
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suffering from symptoms of atresia or malacia. Fibrillar protein collagen is also very 
versatile; capable of being reconstituted into hydrogels, macro-scale constructs such as 
tissue grafts, microspheres for drug-delivery, or cell-seeded scaffolds, all of virtually any 
shape and size [36].  
 While type I collagen holds much promise, few documented attempts have been 
successfully made in creating a mostly- or fully-collagenous stent. Of all recorded papers, 
the closest few, as of today, include an artificial tracheal collagen-coated mesh prosthesis 
which was attempted as a basis for wound healing [33], with a similar type collagen-
coating attempted for a drug-eluting vascular stent [43]; an experimental carinal 
reconstructive prosthesis conjugated with collagen coating was documented [44], and a 
PLGA-collagen hybrid scaffold, reinforced with a copolymer stent and hydrogel, was 
more recently attempted as a means of tracheal defect repair [45]. All these attempts had 
relative success, underscoring the potential of collagen as a viable biomaterial for 
tracheobronchial stent design.  
 With the aid of novel manufacturing methods such as 3D printing, in combination 
with advancements in today’s technological equipment, this research could successfully 
lay the groundwork for a type I collagen, resorbable tracheobronchial stent. 
 While materials, like type I collagen, which are inherently found in the body may 
hold the best solution for compatibility and eventual reintegration of stents for long-term 
recovery, materials that are highly biocompatible and/or bioresorbable are also very 
promising. Among these is polycaprolactone (PCL), a semi-crystalline aliphatic 
biopolymer that has biodegradable and biocompatible traits [46, 47, 48]. Unlike fibrillar 
protein collagen, PCL’s surface hydrophobicity, while good for slowing its degradation 
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rate, undermines its effectiveness in allowing cell adhesion and eventual reintegration 
into local tissue [49, 50, 51]. However, PCL can be broken down by microorganisms 
outside the body quickly, while within the body it is slowly resorbed after the initial 
hydrolysis-based degradation takes place [52]. Surface erosion, or degradation, occurs 
when the surface-level polymer backbone is being cleaved hydrolytically, resulting in 
external polymeric thinning while internally the molecular weight is basically unaffected 
and will remain unchanged while degradation occurs [53]. With erosion of the polymer 
occurring in this fashion, the lifetime of the breakdown process can easily be predicted, 
and release rates for drug eluting implants and similar medical devices are readily 
calculable [54]. This feature gives PCL the ‘bioresorbable’ property that has made it 
popular for implants and tissue engineering scaffolds, sutures, wound dressings, and 
dental devices, among many other medical uses [29].  
 Materials that are deemed bioresorbable tend to double as being biocompatible, 
given that the body’s tissues tolerate that same material well [55]. Being both 
biocompatible and bioresorbable, PCL has ideal rheological properties and can easily exit 
the body harmlessly, while its viscoelastic properties mean production and manipulation 
of the polymer are easy, and degradation time can be specifically tailored to fit the 
particular, necessary device lifetime [29, 54]. Because of its many favorable traits, 
attempts have been made to use PCL to fabricate a tracheobronchial stent for airway 
remodeling in the past [56, 57]. None of these attempts thus far employed novel 3D 
printing methods, or have proven that this material is 3D printing-compatible. 
 The third material studied in this research, TPU, is biologically compatible [58] 
rather than bioresorbable, and has potential for stent making. The mechanical properties 
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of this thermoplastic polyurethane (TPU) compound would make the printing of a great 
variety of personalized stents easily plausible. TPU has high strain recovery and is highly 
tunable or “smart”, meaning it will return to its initial shape; it is light weight and easy to 
process, making it ideal for 3D printing, in addition to being low cost, which makes it 
economical [59, 60].  
 FDM methods like 3D printing require filamentous material input; the heat-based 
extrusion process has the potential to alter material properties, particularly of 
thermoplastic or thermally sensitive substances like TPU. Extruded TPU under repeat 
cyclic-loading and unloading, which are conditions an implanted stent is likely to 
experience during reflexive events such as coughing, eventually exhibit inelastic effects 
such as residual strain, hysteresis loss, and stress-softening; this is usually under maximal 
strain, however [61]. Given thermoplastic polymers have high resilience and low stiffness, 
while handling friction well [62], and because these polymers have shown higher strain 
capability and strain recovery values when copolymeric sequences are more randomly 
distributed [63], the aforementioned problem of inelastic/plastic deformation can be 
worked around.  
 An additional concern for thermoplastic composites in general includes the 
plasticizing effect which moisture absorption has on the material [64, 65]. Medical grade 
thermoplastic polyurethanes have been used in completely moist of fully humid 
environments such as the mouth or intravenously, either for orthodontic purposes or 
vascular grafts, respectively [63, 66]. Based on this information, it can be deduced that if 
TPU can successfully be cross-linked in a manner that creates material insolubility, it is 
possible to employ this biomaterial for tracheobronchial stent printing. While this 
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material has been used in combination with 3D printing in the past, there is no 
documented use of TPU in tracheobronchial stent design as of today. 
 
2.3 Stent Printing Process 
 For this research, FDM printing is the primary method employed for 
biodegradable/biocompatible stent design, given the advantageous feature of obtaining a 
device directly from the input 3D design, which makes it the most-established AM 
method in the medical field today [17, 18]. FDM traditionally only makes use of the 
filament-form of any material; that substance is then directly deposited using a system of 
layers building upon earlier layers, until the final device is formed. Silicone stents have 
been manufacturing using a very similar technique, but often must be injection molded 
and require a lengthy curing process afterward [67, 68, 69]. TPU polymers are flexible 
and share many mechanical properties which are similar to the traditionally used silicone, 
but TPUs are designed to be more 3D printing friendly, while polymers like PCL, or 
biological materials like type I collagen, have not been successfully printed using FDM 
technology; attempting this pioneering process with these materials is also part of the 
focus of this research. 
 As newly available biological materials that increasingly emulate natural tissues 
are becoming widely accepted for use in the medical field, these materials show great 
promise for the future of endoprosthesis [70]. In combination with an innovative stent 
design and manufacturing technique, the creation of a prototype stent not made of 
silicone or metal, but with materials of ideal mechanical properties like thermoplastic 
polyurethanes (TPU) [59, 60, 58], high biocompatibility like polycaprolactone (PCL) [29, 
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57, 71], as well as a biomaterial like fibrillar protein collagen with potential for resorption 
into the airway [36], would provide a novel, unique edge to research at the University of 
South Carolina. 
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CHAPTER 3. STENT TESTING 
 
 
3.1 FDA Non-Clinical Evaluation Requirements 
 
 The FDA requires certain mechanical properties be quantified for non-clinical 
evaluation of stents [72]. However, no widely accepted, industry-standard protocol exists 
for obtaining these properties for airway stents. The FDA publishes specific guidelines 
for vascular stents that can be adapted for airway stents. For this research we performed 
certain basic mechanical analyses, such as tensile testing and compression testing, to 
characterize both the raw materials for each of the stents proposed, as well as the post-
processed form (stent) itself. The significance of these properties to airway stent 
performance will be described in this section.  
After a stent is designed, documented testing is necessary in order to demonstrate 
safety and proper functionality in accordance with FDA guidelines. This allows 
physicians to determine under what conditions, and where, the best stent placement 
should be.  
While no particular FDA protocols are given for airway stents, there are certain 
mandatory, non-clinical engineering data or properties that the FDA requires be 
quantified. Among these requirements are forms of uniaxial compression or elongation 
(extension) testing (Fig. 3.1), to characterize a stent’s performance under short and long-
term external loading/unloading [72]. Stent stress and strain responses determine stent 




Figure 3.1. Some stent characterization tests. Angles of forces applied to stents during various 
standard tests that will determine maximal stress or strain the stent can withstand. 
 
 
yield strength), and its maximal deformation limit, (known as the ultimate tensile strength 
point) for each stent will directly correlate with its clinical performance.  
For certain stent designs, for example mesh stents and expanding stents, the FDA 
also requires particular radial strength and radial stiffness testing unique to each stent’s 
specific dimensions. Material composition also requires certain additional tests for yield 
strength, elastic (Young’s) modulus, and endurance limit, among others [72]. Again, 
these quantify the strength of the stent.  
 
3.2 Expandable or Self-expanding vs. Solid Stents 
 
The stents manufactured in this research are all termed ‘solid’ stents, having the 
straight-tube design similar to the industry gold standard Dumon stent. Solid stents are 
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delivered using rigid bronchoscopy, and are already in the final conformation state they 
have while deployed within the trachea or bronchi; therefore these are not considered 
‘expandable’ stents.  
In contrast, an expandable stent changes shape after insertion. Expandable stents 
are further divided into either balloon-expandable or self-expanding stents. Balloon-
expandable stents are usually delivered via the flexible bronchoscopy method (this 
procedure does not require general anesthesia), and as the name implies, such stents are 
maneuvered into place prior to being expanded to their final conformation. Stents of this 
type are usually tightly wound over a flexible catheter tipped with a small balloon (Fig. 
3.2), which is used to guide the stent into place, then inflated by the physician in order to 
deliver the stent. The balloon is deflated once the stent is placed, and the catheter itself is 
removed. 
 
Figure 3.2. Balloon-expandable stent. Mounted on a flexible catheter and delivered to the 
deployment site, prior to balloon expansion. Once the stent is placed, the balloon is deflated and the 
catheter is removed, leaving the stent in place. Above delivery system is produced by Covidien. 
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 Self-expanding stents are ‘spring loaded’ into special catheters. Once the catheter 
is correctly positioned, the stent is released from the device and immediately expands to 
achieve its final conformation (Fig. 3.3). 
 
Figure 3.3. Schematic of a self-expanding stent and delivery catheter. In 3.3A, both the loading of the stent 
into, and the delivery out of, the instrument is facilitated via a netted sleeve. Illustrated in 3.3B, the stent is 
being compressed as it is loaded into the netted sleeve such that it may deploy and expand to appropriate 
geometry when delivered into the airway. 
 
 Additional properties to report for balloon-expanding and self-expanding stents 
are required by the FDA to determine the recoil and radial outward force exerted by the 
stent on the surrounding tissue. Forces that are too great risk a possibility of damaging 
tissue local to the stent. Weak expansion forces may result in a partially deployed stent, 
which in turn could occlude the area in which the stent was placed, or cause the stent to 
migrate out of the target location. Foreshortening, or the potential change in stent 
dimensions affecting stent length as it is being deployed, must likewise be evaluated [72]. 
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 Testing that exceeds FDA requirements has been undertaken in past research to 
study stent migration and behavior. Such testing includes stent behavior in the tracheal 
region under conditions of coughing, in vivo studies, or development and modeling of 
stent behavior using complex simulation software [75-77]. Such testing is beyond the 










CHAPTER 4. TYPE I COLLAGEN STENT ANALYSIS 
 
 
4.1 Designing and Manufacturing A Simple Tubular Collagen Stent 
 
 One of the goals of this research was to create a simple, smooth-walled stent 
similar to a basic Dumon silicone tube stent. We created three tubular collagen stent 
prototypes with the injection-molding 3D printing process. Such stents allow for 
comparison of the material properties of each the 3D printed stents to the Dumon silicone 
stent that holds de facto go-to status for non-metallic stents.  
While direct FDM printing of gel-like collagen would be most advantageous (see 
Chapter 2), such is not yet possible. Our procedure was to use SLA methods to print a 
mold (Figures 4.1-4.3) from an acrylonitrile butadiene styrene (ABS)-like material. This 
mold was subsequently used for the 3D injection molding of the collagen stent. Injection 
molding was most conducive to working with raw type I fibrillar collagen. A team 
member, using a CAD package, designed the individual parts of the 3D printed mold. 
 The collagen was obtained and prepared from the hide of an 18-month-old bovine 





Figure 4.1. Rod designed using CAD software. It is placed in the center of the mold, allowing for 




Because collagen was demonstrated to be more conducive to the injection 
molding 3D printing method than to the FDM method, simple collagen tubes were 
manufactured via injection molding using standardized methods, and were mechanically 
tested (Appendix A).  
The collagen tubes were already primarily cross-linked via pH crosslinking, in 
order to set each tube in its respective mold. Next, the tubes were further polymerized 
using UV cross-linked via a UV Stratalinker 2400 introducing 0.12 millivolts of UV light 
at a wavelength of 166.7 nm in each burst. Polymerization was done to further increase 




Figure 4.2a. Shell of the mold, designed using CAD software. This design was intended to determine the 
outer diameter of the tube stent. The pinpoint holes in the body of the shell are in the micrometer range; 
these are intended to release pressure when collagen is injected in, as the formation of air bubbles 
compromises stent integrity. 
 
 
The detailed collagen preparation and concentration procedure is included in 
Appendix A. Collagen concentration was determined by a weight percent (wt%) 
calculation: 
 
𝑤𝑡% 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛 =  
𝐷𝑟𝑦 𝐶𝑜𝑙𝑙𝑎𝑔𝑒𝑛
𝑊𝑒𝑡 𝐶𝑜𝑙𝑙𝑎𝑔𝑒𝑛
 𝑥 100%    (Eq. 1) 
 
 
The experimental range of wt% used started with the lowest concentration of 0.5 wt%, 
the next being 0.77 wt%, another concentration at 0.83 wt%, and the highest 
concentration being 3 wt%.  
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Figure 4.2b. Body of the mold shell. Again, the pinpoint holes of 1.25μm diameter intended 
to release pressure from injecting fibrillar type I collagen. The 2.01mm indent is where the 




Figure 4.3. Cap of the mold, designed in CAD. Fits on either end of the rod piece, sealing the 





4.2 Collagen Stent Results 
 
The objective of this research was to use 3D printing methods to manufacture a 
simple cylindrical tube-like collagen stent and test its mechanical properties. These 
stress-strain properties were to then be compared to the average total radial pressure force 
(35kPa) that a tracheomalacial patient’s trachea will experience due to flaccid smooth 
muscle collapse during exhalation. The collagen tubes had a tendency to shrink slightly 
after removal from the molds and storage in HEPES buffer solution. 
Collagen tubes having varying levels of polymerization (0X, 10X, 40X, and 80X) 
were cut into sections of 2.5mm thick, 7mm diameter discs. Compression testing of the 
resulting collagen tubes was undertaken using a rheometer. Individual Young’s moduli 
were calculated, along with stress-strain data, and were plotted (Appendix A). 
Those collagen discs that were only pH cross-linked enough to maintain their 
tubular conformation, yet did not experience UV-polymerization (0X cross-linking), were 
expectedly extremely weak. These discs would deform irreversibly at around 8,500Pa of 
compressive force. However, the average compressive force experienced by the trachea 
of a tracheomalacial patient is 35kPa (Appendix A). No significant differences in 
compressive strength were demonstrated between UV polymerized (10X, 40X, 80X) and 
un-polymerized (0X) collagen discs of the same wt% collagen. Collagen discs at 3 wt% 
of all cross-linking levels displayed greater compressive strength compared to those of 




CHAPTER 5. POLYCAPROLACTONE STENT ANALYSIS 
 
 
5.1 Preparing a PCL Filament 
 
 Few pure polycaprolactone stents have been manufactured in past studies, 
particularly for use in the airway; among these few publications, medical grade PCL has 
primarily been used with other 3D printing methods such as liquid-based SLA or 
injection molding [56, 57, 74]. Prior to this research, medical grade PCL has not been 
demonstrated to have been processed into a filament, or, by extension, used in 
combination with FDM printing. 
 In accordance with the objectives of this research, the PCL filament was created 
via the use of an extruder built for this purpose, its optimal FDM printing conditions were 
determined, and a tubular PCL stent of similar geometry to the Dumon silicone stent was 
printed. This was then mechanically tested to characterize and compare the PCL stent to 
the industry standard Dumon silicone stent. 
In order to determine if PCL was capable of being FDM printed, and what the 
temperature specifications of printing were, 12oz of hobbyist quality ‘Instamorph 
moldable plastic’ polycaprolactone pellets were purchased from Instamorph [78]. Using a 
DSM Xplore Micro 5cc Twin Screw Compounder, the Instamorph polycaprolactone 
pellets were extruded into a 3m long, 1.90mm diameter filament at 90
o
C, 1.7kN, and 
100rpm, with a 1.6mm diameter nozzle tip. The filament was naturally cooled.  
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On a Solidoodle FDM printer, the Instamorph PCL filament was printed at 
various temperatures, beginning with its usual melting point at approximately 60
o
C, 
until an optimal temperature and maximal speed of printing were determined. Based 
on this data, we determined that polycaprolactone was FDM printing compatible. 
Similarly, 500g of medical-grade polycaprolactone (Mn 80,000) was ordered 
from Sigma-Aldrich [79] and was processed into a filament using a DSM Xplore 
Micro 5cc Twin Screw Compounder with similar parameters as above. However, a 
higher temperature of 93-95
o
C was required to extrude pellets into the final 1.6mm 
diameter filament form.  
As the Twin Screw Compounder was not optimized for extruding material 
having the particular viscosity of medical-grade PCL, the Compounder began to singe 
the PCL filament. Burning results in alterations of the properties of the PCL filaments. 
In order to prevent introduction of error, an extruder was specially built to process the 




Figure 5.1. PCL filament extruder schematic. Material composition of main body is stainless steel 
(5.1A, gray and red, 5.1B and C, the red tube); the inner tube is Teflon (5.1A, pale blue, 5.1C, the 





Figure 5.2. Extruder built for manufacturing medical-grade PCL filament. Attached is a 
thermocouple providing heat for the extrusion process. A team member designed the extruder. 
The stainless steel extruder body is 13.45cm long with a 33.30mm outer diameter. The opening 
of the 14.85mm diameter brass tip is 1.58mm diameter. Pellets are poured into 21.55mm inner 
diameter Teflon body, then the plunger is pushed in using a 12-ton hydraulic shop press. 
 
  
 Tensile testing of extruded medical-grade PCL filaments was undertaken to 
characterize material properties compared to the medical-grade silicone of the Dumon 
stent. On a Tinius Olsen 5000, a 1.44mm diameter PCL filament was tested to 
determine material mechanical properties of stress and strain. The Tinius Olsen 5000 
was hooked up to a data acquisitioning device (DAQ) reading voltage output for 
displacement and force into LabView SignalExpress software. Exported data was 





Figure 5.3. Medical-grade PCL filament tensile testing. Average of all trials reported above. PCL 
filament began necking immediately, but was able to continue to stretch without further decrease in 




Figure 5.4. Comparison of medical-grade PCL filament vs. medical-grade silicone. A strip of 
silicone 2 inches long and 5mm in diameter was compared to the 2 inch stretch of 1.44mm diameter 
PCL. Average trials of both being compared, results suggest that PCL can handle a greater force 


































EPCL = 9.90 MPa 
EPCL = 9.90 MPa 
ESi = 4.14 MPa 
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5.2 Printing a Simple, Tubular PCL Stent 
 
 PCL stents were printed using a Solidoodle FDM printer. The basic schematic 
is as follows (Fig. 5.2). Filament is fed between the driver and idler gear. Using 
torque, the gears then feed the filament further into the nozzle where it is then heated; 
the semi-solid material then exits the nozzle tip to print the final product onto a 
temperature-controlled stage that can be raised or lowered. 
 
Figure 5.5. Schematic of an FDM printer. The driver motor turns the toothed primary or ‘driver’ 
gear, while the secondary smooth ‘idler’ gear aids in feeding filament into the nozzle. At the end of 
the nozzle is the heating element that melts the filament, allowing it to be extruded through the tip of 
the print head and used to print a stent. 
 
 Both the Instamorph-grade and medical-grade PCL filaments were printed 
according to the geometries of the Dumon silicone stent. On a Solidoodle FDM 3D 
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printer, printability of Instamorph PCL as a biomaterial was tested. At 70
o
C the 
filament was extruded consistently at 5 minute printing intervals, supporting that PCL 
is viable 3D print-capable material. 
 Similarly, using a Solidoodle FDM printer, higher quality medical-grade PCL 
filament was printed at 200
o
C, generating a 30mm diameter ring. Parameters were 





volume was printed in a vertical orientation. 
Printed stents were then compression tested using a Bose Electroforce 3200 
load frame system (Fig. 5.6), applying 1N of force across the full length of the stent, 
at a crosshead speed of 0.001m/sec. Compression testing methods used in this 
research are similar to the previous stent-testing procedures used by Saito et al., 2002 
and Liu et al., 2011. The medical-grade PCL stents were compared to industry 
standard Dumon silicone stents (Fig. 5.7). 
 
 
Figure 5.6. Compression testing set up. Using the Bose Electroforce 3200, all stent-types underwent 





Figure 5.7. Compression testing of PCL and Dumon stents. The PCL stent segment that was 
compression tested was then normalized along the final length of the final intended stent 
geometry of both the TPU and Dumon silicone stents. However, the PCL compression testing 
was not successful. 
 
 
The final FDM printed PCL stent tested was not the exact length of the testing 
standard Dumon stent. Therefore, a smaller segment of the PCL stent was 
compression tested following the above-mentioned procedure for compression testing. 
The resulting data for the stent segment was then normalized along the final length of 
a PCL stent that would be geometrically identical to the Dumon stent in length. This 






















ESi = 20.48 MPa 
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CHAPTER 6. THERMOPLASTIC POLYURETHANE STENT ANALYSIS 
 
 
6.1 Printing a Simple, Tubular TPU Stent 
 
 A spool of colorless, 1.30mm diameter thermoplastic polyurethane material 
was purchased from Fenner Drives (trade name ‘Ninjaflex’) [80]. The material was 
already in filament form. 
 Tensile testing of a 1.30mm diameter TPU filament was undertaken using a 
Tinius Olsen 5000 tensile tester. Force recording was set to 5% force-recording range 
of the total 5000lb load cell, and extension-recording range was set to a maximum of 
25 inches (Fig. 6.1). All data was collected via a DAQ device using LabView 
SignalExpress software, and exported for processing to Excel (Fig. 6.2). 
 
 
Figure 6.1. Tensile testing experimental setup using the Tinius Olsen 5000. As in 6.1A, each filament 
is set in the clamps, exposing a 2 inch stretch of filament for testing. In 6.1B force and extension 





Figure 6.2. ‘Ninjaflex’ TPU filament tensile testing. Average of all trials reported above. TPU 
filament was able to elastically recover after each test, returning to its same morphology after 
undergoing maximal stretching of 10 inches, prior to slipping out of tensile clamps. 
 
 On a Solidoodle FDM 3D printer, printability of Ninjaflex thermoplastic 
polyurethane as a biomaterial was tested. At 205
o
C the filament was extruded 
consistently onto a 60
o
C heated bed.  The standard print speed of 30mm/s was 
maintained. The resulting proto-stent measured 18.61mm diameter x 3mm thick x 
30mm length. Evidence supports that TPU is viable 3D print-capable material for the 
design of implantable airway stents. 
Resulting TPU stents were then compression tested using a Bose Electroforce 
3200 load frame system (Fig. 5.6), applying 1N of force across the full length of the 
stent, at a crosshead speed of 0.001m/sec. Stress-strain curves as well as percent 
















ETPU = 19.91 MPa 
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used in this research are in accordance with previous stent-testing procedures used by 
Saito et al., 2002 and Liu et al., 2011. 
 
 
Figure 6.3. Compression testing of printed TPU stents vs. Dumon silicone stent. The smaller 




Figure 6.4. Comparison of linearized sections of compression data from silicone and TPU stents. 
This graph more obviously displays the smaller diameter TPU stent’s radial stiffness ran nearly 









































ESi = 20.48 MPa 
ETPU = 32.28 MPa 
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All polymer stent tensile (Fig. 6.5) and compression (Fig. 6.6) testing results were 
compared and plotted. The elastic moduli (E) were also calculated and compared in 
Table 6.1. It was noted that TPU was capable of further displacement during tensile 
testing, however, extension beyond the 12in displacement maximum was disregarded 
as being beyond the scope of research parameters.  
 
 
Figure 6.5. Raw material comparison of PCL, TPU, and silicone. Each filament’s average is plotted 
above. While PCL underwent immediate necking, then maintained load bearing steadily, TPU 
continued to elastically deform. Silicone immediately reached maximal load bearing ability, then 




















EPCL = 13.94 MPa 
ESi = 4.14 MPa 




Figure 6.6. Stent compression comparison. PCL, while having a higher elastic modulus than 
Silicone or TPU, lacked the stiffness of the other stent materials of identical size. PCL 
compression test failure meant the data was not included. 
 
 
Testing parameters and results are supported by previously published results 
for elastic moduli of silicone, PCL, and TPU materials. The general acceptable range 
for silicone modulus is between 2-6MPa [82], although up to 10-15MPa is not 
uncommon for medical grade silicone, particularly for airway stents [19, 83]. The 
general elastic modulus for medical grade PCL (Mn 80,000) is approximately 14-
16.9MPa, although changes in polymer chain microstructure can affect this [84]. For 
TPU, the modulus range begins at 10MPa and goes up to approximately 5GPa, 
depending on the specific purpose for TPU [85].  
Elastic modulus values for a standard tubular stent made from each respective 





















ESi = 20.48 MPa 
ETPU = 32.28 MPa 
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modulus for the Dumon silicone stent was not available for comparison to measured 
values during compression testing, due to the proprietary nature of the product 
specifications. While for medical applications acceptable silicone elastic moduli vary 
anywhere from 3-30MPa [86], and stent elastic moduli must be at least 15MPa for 
pulmonoscopic insertion [87], the silicone stent tested had an average elastic modulus 
of 20.48MPa. A PCL stent modulus value can be as high as 352MPa depending on 
processing method [88, 89], though no standardized value for a pure PCL tube stent 
has yet been published. Compression results were unsuccessful so the elastic modulus 
was not determined. For the TPU stent, an elastic modulus of 32.28MPa resulted.  
 
Table 6.1. Comparison of material elastic moduli measured, and respective industry standards. 
 
Material 






Silicone stent (Dumon)  20.48* 






TPU filament   
 
19.91 
TPU stent     32.28 
where (*) represents unavailable data due to intellectual property. 
 
 
Again, the geometry of both TPU and PCL stents were identical to the Dumon silicone 
stent tested, with the exception that the shorter PCL stent segment was tested and data 
normalized along final stent length to match the Dumon and TPU stents. 
Elastic modulus data for raw material and each FDM printed stent are verified 
by existing publications [84-86, 88, 89], suggesting values for compression and tensile 
testing align with acceptable stent properties.  
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CHAPTER 7. SUMMARY AND CONCLUSIONS 
 
Tracheomalacia, in the forms of esophageal atresia or trachoesophageal fistula 
formation, can be treated with stenting. Migration, inflammation and granulation tissue 
and fistula formation commonly occur with long-term stenting, due mostly to the limited 
material types of existing stents. 
Stenting has improved enormously since the 1900s when it first began. There is 
still much room to grow, and material science has since advanced further. From among 
the many advanced materials available today, type I fibrillar collagen, polycaprolactone 
polymer, and thermoplastic polyurethane polymer were explored for this research. The 
goals of this research were to demonstrate 3D-printing capability of each polymer 
explored, to mechanically test the resulting printed stent, and to compare these stent 
results to the current industry standard: silicone stents. 
This research identified the potential of using FDM printing for quick, on-site 
manufacturing of simple stents. This indicates FDM is indeed a viable 3D printing 
method for polymer stent manufacturing in the future, and should be further explored. 
The FDM printability-analysis demonstrated medical-grade PCL can be confirmed to 
print under carefully maintained conditions of 120-130
o
C, and a rate of 8mm/sec. FDM 
printability of TPU has been reaffirmed, and potential applications as a stent were 
explored mechanically. TPU results were similar to medical-grade silicone polymer. 
This research contributed to furthering the advancement of stent development for 
tracheobronchial implantation by exploring three potential materials from which tracheal 
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stents can be manufactured. Stent manufacturing was undertaken using FDM printing 
methods. Each of the polymer materials was compared to the industry standard silicone 
polymer. Testing results suggest that biocompatible/bioresorbable PCL, and 
biocompatible/biodegradable TPU are able to handle equal or greater compressive loads 
than silicone before plastic deformation occurs. Collagen proto-stents that were 
manufactured were of 3wt% or less collagen concentration, and were not able to achieve 
the same load-bearing ability equal to the polymers tested.  
 Linear regions of stent stress-strain curves for each material were plotted and 
compared. Results suggest very similar behavior between TPU-based and silicone-based 
stents. Pure PCL showed greater elasticity than silicone, and thus was not as stiff. While 
the PCL compression testing was unsuccessful, the segment tested lacked equal or greater 
stiffness compared to silicone or TPU. Further testing, printing of a full-length PCL stent, 
and continuous tweaking of printing parameters for PCL may result in a PCL stent with 
varied elasticity, as well as a stiffer PCL stent. 
This research identified the potential of using type I fibrillar collagen for stenting. 
Tubes were formed through injection molding 3D printing methods, yet higher collagen 
wt% levels and even greater levels of UV polymerized cross-linking should be explored. 
Analysis of collagen proto-stents demonstrated collagen tube compression loading 
maxima (Appendix A). Results suggest the tubes need to be made using a greater 
concentration of collagen to withstand the average 35kPa forces experienced by the 
trachea in a case of tracheomalacia. With the current collagen concentration method, it is 
difficult to concentrate beyond 3wt%; revisions to the protocol could be undertaken to 
improve this.  
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 Overall, these results are very promising. Through this research, material 
printability of type I fibrillar collagen, PCL, and TPU were determined, along with tensile 
and compressive strengths of stents manufactured in comparison to silicone. Results 
suggest TPU and PCL show promise as alternatives to silicone polymer stents as an 
industry standard in treatment of tracheomalacia. 
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CHAPTER 8. FUTURE WORK 
 
 
While this research presented an overview of the process of creating a stent via 
AM methods of FDM printing, there are still points which need addressing. First, the 
stents were all manufactured in the form of a simple cylindrical tube much like the 
Dumon stent. For our purposes this simple geometry was justified, however, more 
complicated stent geometries such as mesh-stents are where future research could be 
directed. 
 Continuing to adjust parameters for collagen tube stent stiffness to attempt to 
identify ideal material UV-polymerization levels should not be excluded from future 
research. As well, future studies should include additional measurements with a larger 
sample size of collagen tube stents over a greater range of crosslinking levels. PCL 
printing parameters can also, through further exploration, possibly offer stents with 
differing elasticity such that a slightly stiffer PCL stent, at the full of a Dumon stent, can 
be printed.  
 The present research was limited to printing of basic stent geometries and 
mechanically testing each stent for characterization of stent behavior, similar to tests 
undertaken in past research. This was done under the assumption that the materials were 
likely biocompatible when post-processed into stents. While justified for the scope of this 
research, integration of in vitro testing of processed materials is required to support the 
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APPENDIX A. COLLAGEN TUBE DATA  
 
Collagen Tube Data in collaboration with Senior Design Group “A’ris Bioinnovations”: 




Figure A.1. 0.5 wt% collagen 
 
 










Figure A.4. Rheometer results for un-UV-cross-linked collagen. Two samples were used, 
entered irreversible deformation around strain levels of 0.678, and a stress of approximately 





Figure A.5. Rheometer results for collagen UV cross-linked for 1 burst of 750J, i.e. “weakly cross-
linked”. Plastic deformation occurred after stresses of 6903Pa and strain levels reached 0.556 for the 
first repetition, and after stresses of 6011Pa with strain levels of 0.585 for the second repetition. Being 
closer to the 35kPa the trachea exerts, the material may not fail if stresses experienced by the proto-stent 




Figure A.6. Rheometer results for collagen UV-cross-linked for 10 bursts @ 750J each, or “slightly more 
cross-linked”/”moderately cross-linked”. Both samples underwent plastic deformation close to 0.5 strain 
levels. The collagen disc for repetition 1 withstood approximately 5201kPa of compressive force, while the 
disc for repetition 2 withstood about 6765kPa of force. Again, pressures exerted by the trachea must be 





Figure A.7. Compressive modulus testing comparing all collagen stents at 3 wt% concentration. 
Where *=(-39089.20, 43118.66),  #=(-38405.64, 28659.52), $=(-40625.24, 34908.59). No significant 




Figure A.8. Results of compression repetition on collagen that has not been UV-cross-linked. Despite 
greater collagen concentration percentage, lack of UV polymerization leaves maximal compressive 
forces of 9,073Pa for the first repetition, 9,493Pa for repetition 2, and 9,273Pa for repetition 3. These 





Figure A.9. Results of compression repetition on collagen tube discs after 80 bursts of UV cross-
linking. Despite higher UV polymerization and more concentrated collagen wt%, the maximal 
stress values for each repetition are less than 35kPa, possibly resulting in cyclic failure if stresses 




Figure A.10. Amount of cross-linking vs. compressive strength of the 0.83 wt% stent. Higher 
cross-linking of a more concentrated collagen percentage, compared to an uncross-linked stent of 





Figure A.11. Results of compression on mid-to-high collagen concentration that is not UV 
cross-linked. Plastic deformation occurs at a strain level of 0.73, with stress values at about 
9,972Pa. Again, compared to the average 35kPa stress exhibited on a tracheomalacial patient’s 
airways, 27% of this level of pressure applied locally would likely cause this collagen proto-




Figure A.12. Results of compression testing for a mid-to-high collagen concentration wt% 
stent that underwent 10 bursts of UV cross-linking. As the stents begin to deform after 8,288Pa 
of stress, at approximately 23.68% of the total radial pressure a tracheomalacial patent’s 
tracheal wall would exert during exhalation (35kPa) this stent with low-level UV 





Figure A.13. Results of compression repetition for a mid-to-high collagen concentration stent that 
underwent 40 bursts of UV cross-linking. Surprisingly, compression testing revealed that these 
collagen discs were weaker than those that were UV polymerized at only 10 bursts. This could, 




Figure A.14. Comparing all the results for 0.77 wt% collagen discs. It is likely that slight damage to 
the 40X collagen discs prior to testing resulted in weaker stress-strain values than the 10X collagen 





Figure A.15. Comparing all collagen concentration percentage results. Expectedly, the highest collagen 
concentration had the greatest compressive strength. There was little difference between collagen 




Collagen Preparation Procedure 
(Provided by Dr. Mike Yost’s Lab) 
 
Collagen is prepared from hide of an 18-month-old bovine steer (Caughman’s in 
Lexington, SC) 
 
1. Cut hide into 4x6 cm strips and freeze prior to processing. 
2. Remove all superficial epidermis including the hair and follicle pits. Depending 
on the hide, hair clippers may be needed to cut hair off first. 
 
3. Wash collagen with running tap water to remove all hair. 
4. Incubate collagen overnight at 4oC in the fridge, in 2% Ca(OH)2 solution per hide 
weight (lime water). Mix well and place in tumbler. Incubate at 4
o
C in the fridge. 
 
5. Wash the collagen under running water. The collagen is placed in 1M NaCl 
solution and left at 4
o
C in the fridge. The solution pH should be brought to 5 with 
1M HCl solution. 
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6. After the pH remains stable at 5, wash the collagen in DI water until water is clear 
and the conductivity is at 100μS/cm to make sure all the salt is washed out. If not 
going to process right away, freeze it. 
 
7. Thaw out the de-limed collagen, or continue processing. Cut the hides into 1 inch 
square pieces. 
 
8. Put the collagen in cold 0.5M CH3COOH (acetic acid) solution. Then add pepsin 
(50:1 hide weight to pepsin ratio). Incubate overnight at 4
o
C in the fridge. 
 
9. Clean the meat grinder well to remove any rust. Place lard to lubricate. Run ice 
through the grinder until it comes out clean. Add 2 pieces of hide, followed by a 
half handful of ice. Wait until it comes out. Repeat it until all the collagen is 
grinded. Collect the collagen in a stainless steel bowl. 
 
10. After the collagen has been ground, add cold 0.5M CH3COOH (acetic acid) 
solution. Mix in the kitchen aid mixer until you reach a soupy consistency. 
Gradually add acetic acid while mixing until you get the right consistency. Use 
1M HCl to bring the pH down to 3-4.5, or a lower pH if necessary. Incubate 
overnight at 4
o
C in the fridge. 
 
11. The next day, check the pH and adjust to a pH 3 as needed. 
12. Clean the press. Put the collagen pieces through the press. The mesh filter must be 
cleaned with hot water frequently to avoid clogging. 
 
13. Add cold 0.5M CH3COOH (acetic acid) to the pressed collagen and mix well until 
liquid. Measure how much acid is added to the collagen. 
 
14. Add 1M NaCl (taking into account the amount of acetic acid that was added in 
step 13) until the collagen comes out of solution. Up to 2M NaCl can be added. 
Incubate overnight at 4
o
C in the fridge. 
 
15. The next day, spin down the collagen to get rid of the water at 5000-7000 rpm for 
30 minutes at 4
o
C. It will take several spins to collect all of the collagen. Make 
sure the collagen is kept cold at all times. **When all sides of centrifuge are 
weighted, collagen collection works best. 
 
16. After collecting the collagen, add ice water and adjust the pH to 5.5 with 1M 
NaOH. A large amount will have to be used to bring the pH up. 
 
17. Once the pH is around 4, incubate overnight at 4oC in the fridge. 
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18. The next day, adjust the pH to 5.5. The solution must have enough volume to put 
into dialysis tubing. Place the dialysis tubes containing the collagen into beakers 
of cold water and store at 4
o
C in the fridge. 
 
19. Keep changing the water at least twice a day for several days until the 
conductivity reads 50μS/cm. 
 
20. Once the conductivity has reached the desired value, remove the collagen from 






Collagen Concentrating Procedure 
 
1. Determination of collagen concentration as: 
(Dry collagen /wet collagen) x 100 
 
2. Raw collagen was placed in a conical centrifuge tube to be spun down at 4000 rpm for 
30 minutes until all collagen is collected at the bottom of the tube. 
 
3. Excess water was removed in addition to any diluted collagen floating on the top. 
Concentrated collagen was stored overnight at 4
o
C in the fridge. 
 
a 
